Hls Therapeutics, Inc. · TSX:HLS
Hls Therapeutics — Q1 2026 Earnings Presentation
20 slides from Hls Therapeutics's earnings presentation, May 15, 2026
Slide 1: Q1 2026 Earnings Call – May 15, 2026
Q1 2026 Earnings Call – May 15, 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this presentation are “forward-looking statements”. Any statements contained in this presentation. These factors should be considered statements that express or involve discussions with respect to predictions, carefully and prospective investors shoul
Slide 3: HLS is in a Strong Position Today
HLS is in a Strong Position Today 01 02 03 Strengthened Key catalyst: Acceleration Operations & Financials NILEMDO launched beyond 2026 Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary mate
Slide 4: Strengthened Operations and Financials
Strengthened Operations and Financials 15% 78% 80% 52% Vascepa revenue Adj EBITDA growth Cash from operations Net debt growth in Q1 2026 (excl royalties) in two years growth in Q1 2026 reduction in two years Adj. EBITDA ex Royalties Net Debt (US$M) (US$M Trailing Twelve Months) 80 20 18.5 70 67 18 1
Slide 5: The Portfolio
The Portfolio NILEMDO / NEXLIZET® the new growth engine Growing VASCEPA® Stable CLOZARIL® base Illustrative purposes only; not financial guidance Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may
Slide 6: Three Products, One Goal
Three Products, One Goal Reducing CV Risk for More Canadians VASCEPA® NILEMDO NEXLIZET®* First/only in Well-tolerated, Large outcomes trials Many years of real- Integrated into global Go-to-market class medicines all oral portfolio demonstrated CV world evidence treatment guidelines model synergies
Slide 7: The NILEMDO + NEXLIZET Opportunity: an Illustrative Example
The NILEMDO + NEXLIZET® Opportunity: an Illustrative Example 5M+ Canadians with CVD/ elevated CV risk1 500,000 X 10–20% Not at LDL goal and/or Market statin intolerant2 Penetration ~3M On statins1 = C$50M–100M Revenue Illustrative analysis based on range of net pricing and patient compliance assumpt
Slide 8: Accelerating Growth Building
2026 2027 Building Accelerating Momentum Growth $56–60M $18.5–21M Revenue Adj. EBITDA Mid single-digit % growth Relatively flat — driven by CV portfolio absorbing launch costs Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking
Slide 9: Ontario patient volumes increased in March & April
Ontario patient volumes increased Continued growth ~50% market in March & April in Western Canada share maintained Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims
Slide 10: Continued Prescribing Growth
VASCEPA® TRx Units (thousands) Since Launch - Canada Continued 180 Prescribing 160 140 Growth 120 100 +18% 80 Q1 2026 TRx 60 vs Q1 2025 Patent protection 40 through the late 20 2030’s 0 2020 2021 2022 2023 2024 2025 Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qual
Slide 11: Broad Indications Will Support Target Patient Populations in Need
Broad Indications Will Support Target Patient Populations in Need NILEMDO INDICATIONS Primary Hyperlipidemia 5M+ (LDL-C reduction) Canadians with CVD/ elevated CV risk1 500,000 Prevention of Not at LDL goal and/or CV events statin intolerant2 ~3M On statins1 Only oral non-statin indicated for both L
Slide 12: NILEMDO & NEXLIZET: Affordable Oral Treatments Beyond Statins
NILEMDO & NEXLIZET®: Affordable Oral Treatments When Patients Need Options Beyond Statins STATIN THERAPIES NON-STATIN THERAPIES Ezetimibe PCSK9i mAbs PCSK9i siRNA Mostly CV Risk Reduction Generic Indication 1 Primary Prevention First-line, widely used 1 Secondary Prevention Combinable with LDL-C Low
Slide 13: High levels of awareness and interest in bempedoic acid/NILEMDO
NILEMDO High levels of awareness and interest in bempedoic acid/NILEMDO Key Findings from Pre-Launch Market Research1 >50% >90% >80% of patients Total awareness Physicians willing to Rx not adequately controlled of bempedoic acid / NILEMDO bempedoic acid / NILEMDO on first line treatment 1 Baseline
Slide 14: Target public payer listings in early 2027
NILEMDO Secure listings with Minimize access Set up criteria to "tuck in" Private Payer key large insurers barriers, i.e. prior NEXLIZET® when Health Progress Goals in 2026 authorization Canada approved PLANS REPRESENT ~40% NOW CURRENTLY LISTED FULL BENEFIT; NO PRIOR AUTHORIZATION of private lives T
Slide 15: Multiple CV Portfolio Catalysts Ahead
Multiple CV Portfolio Catalysts Ahead All CV product patents extend to late 2030’s Meaningful revenue expansion Public 2027+ NEXLIZET® approval & launch reimbursement listings H1 2027 Private payer H1 2027 Commercial listings launch In progress NILEMDO Q2 2026 Available Q1 2026 Vascepa® to 2039 NILE
Slide 16: Q1 2026 Financial Review
Q1 2026 Financial Review Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update HLS THERAPEUTICS INC. 16
Slide 17: Expect Quarterly Seasonality to Continue in 2026
Expect Quarterly Seasonality to Continue in 2026 Adjusted EBITDA by Quarter (millions) USD 5.6 5.7 5.2 4.9 4.3 4.1 3.8 3.5 2.7 $18.5-21M Adj. EBITDA 2026 Guidance Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 NILEMDO launch costs weighted towards 1H 2026 with Adj. EBITDA ma
Slide 18: Balanced Capital Allocation
Balanced Capital Allocation 01 02 03 Portfolio Debt Share expansion repayment buyback Toronto Stock Exchange (TSX) - HLS Provided as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update HLS THERA
Slide 19: HLS: a strong foundation for growth
HLS: a strong foundation for growth 01 02 03 Strengthened Key catalyst: Acceleration Operations & Financials NILEMDO launched beyond 2026 80% cash from operations growth in Q1’26 Clear unmet need in large target population NILEMDO public reimbursement 78% two-year Adj. EBITDA1 growth High baseline a
Slide 20: Q1 2026 Earnings Call – May 15, 2026
Q1 2026 Earnings Call – May 15, 2026